Poor
Not Aligned
Patient Risk:
Low
Summary
The AI statements concern patent and biosimilar exclusivity timing, which are not addressed in the provided ENTYVIO prescribing information excerpts. Therefore, the statements cannot be verified against the label and are treated as unsupported for label alignment purposes.
Category Scores
Accurate Statements
Unsupported Statements
Vedolizumab’s U.S. patent situation depends on which specific patent family is meant (active ingredient, formulation, dosing/combinations, or manufacturing/process).
No patent-family or intellectual property content is present in the provided prescribing information excerpts.
Different patents expire on different dates for vedolizumab.
No statements in the provided prescribing information excerpts address patent expiration dates.
The earliest patent expiry date is not always the same as the last date that blocks generic or biosimilar competition for vedolizumab.
The provided prescribing information excerpts do not discuss generic/biosimilar blocking, exclusivity, or timing.
Biosimilar entry may be delayed after a patent expires by other exclusivities, including regulatory exclusivities.
No discussion of biosimilar entry delays, regulatory exclusivities, or comparable IP/exclusivity mechanisms appears in the provided label excerpts.
Biosimilar launch timing may be driven by the 'last-to-expire' intellectual property listed for the product rather than a single earliest expiry.
The provided prescribing information excerpts do not mention 'last-to-expire' IP, product exclusivity listings, or launch timing.
Contradictions
Important Omissions
No label-relevant patient safety content (e.g., indications, dosage, contraindications, warnings/precautions, drug interactions) was provided or assessed by the AI relative to the prescribing information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Patent/biosimilar timing statements do not directly instruct dosing, contraindications, or patient management based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The statements are about patents/exclusivities and are not supported or addressed in the provided ENTYVIO prescribing information excerpts, so label alignment cannot be established.
Suggested Improvement
Limit claims to content actually present in the provided FDA-approved prescribing information or provide the specific label passages that discuss IP/exclusivity if available.